KB-R7785

• Description :

  KB-R7785 is a matrix metalloproteinase (MMP) inhibitor, which improves insulin sensitivity by inhibiting TNF-α production. KB-R7785 can be used for diabetes research. KB-R7785 has a protective efficacy against focal cerebral ischemia[1][2].

• UNSPSC :

  12352005

• Target :

  MMP

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease; Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/kb-r7785.html

• Purity :

  99.90

• Solubility :

  DMSO : 20 mg/mL (ultrasonic)

• Smiles :

  ONC([C@@H](C)[C@@H](CC(C)C)C(N[C@@H](C1=CC=CC=C1)C(NC)=O)=O)=O

• Molecular Formula :

  C18H27N3O4

• Molecular Weight :

  349.42

• References & Citations :

  [1]Morimoto Y, et al. KB-R7785, a novel matrix metalloproteinase inhibitor, exerts its antidiabetic effect by inhibiting tumor necrosis factor-alpha production. Life Sci. 1997;61 (8) :795-803.|[2]Jiang X, et al. Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. Neurosci Lett. 2001 Jun 1;305 (1) :41-4.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [168158-16-5]